Kidney Cancer, Version 2.2024 Featured Updates to the NCCN Guidelines

被引：59

作者：

Motzer, Robert J. ^{[1
]}

Jonasch, Eric ^{[2
]}

Agarwal, Neeraj ^{[3
]}

Alva, Ajjai ^{[4
]}

Bagshaw, Hilary ^{[5
]}

Baine, Michael ^{[6
]}

Beckermann, Kathryn ^{[7
]}

Carlo, Maria I. ^{[1
]}

Choueiri, Toni K. ^{[8
]}

Costello, Brian A. ^{[9
]}

Derweesh, Ithaar H. ^{[10
]}

Desai, Arpita ^{[11
]}

Ged, Yasser ^{[12
]}

George, Saby ^{[13
]}

Gore, John L. ^{[14
]}

Gunn, Andrew ^{[15
]}

Haas, Naomi ^{[16
]}

Johnson, Michael ^{[17
,18
]}

Kapur, Payal ^{[19
]}

King, Jennifer ^{[20
]}

Kyriakopoulos, Christos ^{[21
]}

Lam, Elaine T. ^{[22
]}

Lara, Primo N. ^{[23
]}

Lau, Clayton ^{[24
]}

Lewis, Bryan ^{[25
]}

Madoff, David C. ^{[26
]}

Manley, Brandon ^{[27
]}

Michaelson, M. Dror ^{[28
]}

Mortazavi, Amir ^{[29
,30
]}

Ponsky, Lee ^{[31
,32
]}

Ramalingam, Sundhar ^{[33
]}

Shuch, Brian ^{[34
]}

Smith, Zachary L. ^{[17
,18
]}

Sosman, Jeffrey ^{[35
]}

Sweis, Randy ^{[36
]}

Zibelman, Matthew ^{[37
]}

Schonfeld, Ryan ^{[38
]}

Stein, MaryElizabeth ^{[38
]}

Gurski, Lisa A. ^{[38
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Commack, NY 11725 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[3] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[4] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA

[5] Stanford Canc Inst, Stanford, CA USA

[6] Fred & Pamela Buffet Canc Ctr, Omaha, NE USA

[7] Vanderbilt Ingram Canc Ctr, Vanderbilt, TN USA

[8] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[9] Mayo Clin, Comprehens Canc Ctr, Jacksonville, FL USA

[10] UC San Diego Moores Canc Ctr, San Diego, CA USA

[11] UCSF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[12] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Mcadoo, PA USA

[13] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[14] Fred Hutchinson Canc Ctr, Sunnyside, WA USA

[15] UAB, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[16] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA

[17] Barnes Jewish Hosp, Siteman Canc Ctr, Washington, DC USA

[18] Washington Univ, Sch Med, Washington, DC USA

[19] UT Southwestern Simmons Comprehens Canc Ctr, Dallas, TX USA

[20] Indiana Univ, Melvin & Bren Simon Comprehens Canc Ctr, Indianapolis, IN USA

[21] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[22] Univ Colorado, Canc Ctr, Denver, CO USA

[23] Uc Davis Comprehens Canc Ctr, Davis, AL USA

[24] City Hope Natl Med Ctr, Monrovia, CA USA

[25] KidneyCAN, Omaha, NE USA

[26] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA

[27] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[28] Massachusetts Gen Hosp, Canc Ctr, Charlestown, MA USA

[29] Ohio State Univ, James Canc Hosp, Comprehens Canc Ctr, Columbus, OH USA

[30] Solove Res Inst, Columbus, OH USA

[31] Univ Hosp, Case Comprehens Canc Ctr, Seidman Canc Ctr, Cleveland, OH USA

[32] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[33] Duke Canc Inst, Durham, NC USA

[34] UCLA, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[35] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL USA

[36] UChicago Med Comprehens Canc Ctr, Maywood, IL USA

[37] Fox Chase Canc Ctr, Oreland, PA USA

[38] Natl Comprehens Canc Network, Rockledge, PA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2024年 / 22卷 / 01期

关键词：

RENAL-CELL CARCINOMA; LENVATINIB PLUS PEMBROLIZUMAB; EXTENDED FOLLOW-UP; PHASE-III TRIAL; OPEN-LABEL; INTERFERON-ALPHA; RANDOMIZED PHASE-3; 1ST-LINE TREATMENT; DOSE INTERLEUKIN-2; 2ND-LINE TREATMENT;

D O I：

10.6004/jnccn.2024.0008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on the systemic therapy options for patients with advanced RCC and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Kidney Cancer.

引用

页码：4 / 16

页数：13

共 108 条

[1] Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study [J].

Albiges, L. ;

Rini, B. I. ;

Peltola, K. ;

Oria, G. A. De Velasco ;

Burotto, M. ;

Rodriguez, C. Suarez ;

Ghatalia, P. ;

Iacovelli, R. ;

Lam, E. T. ;

Verzoni, E. ;

Gumus, M. ;

Stadler, W. M. ;

Kollmannsberger, C. K. ;

Melichar, B. ;

Venugopal, B. ;

Wang, A. ;

Perini, R. ;

Vickery, D. ;

Powles, T. B. ;

Choueiri, T. K. .

ANNALS OF ONCOLOGY, 2023, 34 :S1329-S1330

[2] Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma [J].

Amzal, Billy ;

Fu, Shuai ;

Meng, Jie ;

Lister, Johanna ;

Karcher, Helene .

PLOS ONE, 2017, 12 (09)

[3]

[Anonymous], 2021, Tivozanib capsules for oral use. Prescribing information

[4]

[Anonymous], Cancer Stat Facts: Kidney and Renal Pelvis Cancer

[5]

[Anonymous], 2023, Belzutifan tablets for oral use. Prescribing information

[6] Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial [J].

Armstrong, Andrew J. ;

Halabi, Susan ;

Eisen, Tim ;

Broderick, Samuel ;

Stadler, Walter M. ;

Jones, Robert J. ;

Garcia, Jorge A. ;

Vaishampayan, Ulka N. ;

Picus, Joel ;

Hawkins, Robert E. ;

Hainsworth, John D. ;

Kollmannsberger, Christian K. ;

Logan, Theodore F. ;

Puzanov, Igor ;

Pickering, Lisa M. ;

Ryan, Christopher W. ;

Protheroe, Andrew ;

Lusk, Christine M. ;

Oberg, Sadie ;

George, Daniel J. .

LANCET ONCOLOGY, 2016, 17 (03) :378-388

[7] The oral HIF-2 [alpha] inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study. [J].

Bauer, Todd Michael ;

Choueiri, Toni K. ;

Papadopoulos, Kyriakos P. ;

Plimack, Elizabeth R. ;

Merchan, Jaime R. ;

McDermott, David F. ;

Michaelson, Dror M. ;

Appleman, Leonard Joseph ;

Thamake, Sanjay ;

Perini, Rodolfo F. ;

Park, Eric Kristopher ;

Jonasch, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)

[8] Increasing the evidence for surveillance of metastatic renal cancer [J].

Bex, Axel .

CANCER, 2021, 127 (13) :2184-2186

[9] Safety and efficacy of everolimus in patients with non-clear cell renal cell carcinoma refractory to VEGF-targeted therapy: Subgroup analysis of REACT. [J].

Blank, Christian U. ;

Bono, Petri ;

Larkin, James M. G. ;

Gogov, Svetozar ;

Panneerselvam, Ashok ;

Garay, Carlos A. ;

Gruenwald, Viktor .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)

[10]

Burotto M, 2023, J CLIN ONCOL, V41

← 1 2 3 4 5 6 7 8 9 10 →